Sabal Trust’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $21.2M | Buy |
837,870
+55,705
| +7% | +$1.46M | 1.18% | 43 |
|
|
2024
Q4 | $20.8M | Sell |
782,165
-59,705
| -7% | -$1.62M | 1.2% | 40 |
|
|
2024
Q3 | $24.4M | Sell |
841,870
-10,694
| -1% | -$312K | 1.33% | 38 |
|
|
2024
Q2 | $23.9M | Sell |
852,564
-30,625
| -3% | -$843K | 1.42% | 33 |
|
|
2024
Q1 | $24.5M | Sell |
883,189
-11,699
| -1% | -$325K | 1.42% | 32 |
|
|
2023
Q4 | $25.8M | Buy |
894,888
+18,493
| +2% | +$559K | 1.58% | 29 |
|
|
2023
Q3 | $29.1M | Buy |
876,395
+4,363
| +0.5% | +$154K | 1.94% | 21 |
|
|
2023
Q2 | $32M | Buy |
872,032
+14,176
| +2% | +$552K | 2.03% | 16 |
|
|
2023
Q1 | $35M | Buy |
857,856
+20,237
| +2% | +$874K | 2.44% | 12 |
|
|
2022
Q4 | $42.9M | Sell |
837,619
-4,365
| -0.5% | -$209K | 2.92% | 3 |
|
|
2022
Q3 | $36.8M | Buy |
841,984
+9,672
| +1% | +$470K | 2.78% | 6 |
|
|
2022
Q2 | $43.6M | Sell |
832,312
-3,833
| -0.5% | -$195K | 3.13% | 3 |
|
|
2022
Q1 | $43.3M | Sell |
836,145
-15,439
| -2% | -$801K | 3% | 4 |
|
|
2021
Q4 | $50.3M | Sell |
851,584
-7,885
| -0.9% | -$391K | 3.19% | 2 |
|
|
2021
Q3 | $37M | Buy |
859,469
+6,020
| +0.7% | +$267K | 2.64% | 9 |
|
|
2021
Q2 | $33.4M | Buy |
853,449
+15,952
| +2% | +$620K | 2.41% | 15 |
|
|
2021
Q1 | $30.3M | Buy |
837,497
+47,726
| +6% | +$1.69M | 2.25% | 16 |
|
|
2020
Q4 | $29.1M | Sell |
789,771
-37,659
| -5% | -$1.38M | 2.34% | 15 |
|
|
2020
Q3 | $28.8M | Sell |
827,430
-6,659
| -0.8% | -$233K | 2.51% | 15 |
|
|
2020
Q2 | $25.9M | Sell |
834,089
-11,908
| -1% | -$405K | 2.42% | 18 |
|
|
2020
Q1 | $26.2M | Sell |
845,997
-11,691
| -1% | -$398K | 2.94% | 12 |
|
|
2019
Q4 | $31.9M | Buy |
857,688
+18,013
| +2% | +$642K | 2.53% | 15 |
|
|
2019
Q3 | $28.6M | Buy |
839,675
+65,559
| +8% | +$2.38M | 2.31% | 25 |
|
|
2019
Q2 | $31.8M | Buy |
774,116
+6,645
| +0.9% | +$264K | 2.8% | 8 |
|
|
2019
Q1 | $30.9M | Sell |
767,471
-24,119
| -3% | -$966K | 2.75% | 6 |
|
|
2018
Q4 | $32.8M | Sell |
791,590
-58,781
| -7% | -$2.44M | 3.36% | 1 |
|
|
2018
Q3 | $35.6M | Sell |
850,371
-11,134
| -1% | -$429K | 3.14% | 2 |
|
|
2018
Q2 | $29.7M | Buy |
861,505
+7,858
| +0.9% | +$269K | 2.82% | 3 |
|
|
2018
Q1 | $28.7M | Sell |
853,647
-157,337
| -16% | -$5.41M | 2.75% | 7 |
|
|
2017
Q4 | $34.7M | Buy |
1,010,984
+9,515
| +1% | +$324K | 3.54% | 2 |
|
|
2017
Q3 | $33.9M | Buy |
1,001,469
+255,132
| +34% | +$8.2M | 3.39% | 2 |
|
|
2017
Q2 | $23.8M | Buy |
746,337
+42,887
| +6% | +$1.35M | 2.5% | 20 |
|
|
2017
Q1 | $22.8M | Buy |
703,450
+111,901
| +19% | +$3.53M | 2.55% | 23 |
|
|
2016
Q4 | $18.2M | Sell |
591,549
-88,637
| -13% | -$2.71M | 1.99% | 33 |
|
|
2016
Q3 | $21.9M | Buy |
680,186
+5,392
| +0.8% | +$180K | 2.42% | 26 |
|
|
2016
Q2 | $22.5M | Buy |
674,794
+22,578
| +3% | +$721K | 2.6% | 24 |
|
|
2016
Q1 | $18.3M | Buy |
652,216
+54,884
| +9% | +$1.57M | 2.18% | 30 |
|
|
2015
Q4 | $18.3M | Buy |
597,332
+164
| +0% | +$5.16K | 2.39% | 28 |
|
|
2015
Q3 | $17.8M | Buy |
597,168
+576,813
| +2,834% | +$18.5M | 2.49% | 27 |
|
|
2015
Q2 | $648K | Sell |
20,355
-16
| -0.1% | -$521 | 0.08% | 67 |
|
|
2015
Q1 | $672K | Sell |
20,371
-1,356
| -6% | -$43.1K | 0.09% | 65 |
|
|
2014
Q4 | $642K | Sell |
21,727
-2,167
| -9% | -$62.1K | 0.08% | 67 |
|
|
2014
Q3 | $671K | Sell |
23,894
-2
| -0% | -$56 | 0.09% | 66 |
|
|
2014
Q2 | $673K | Buy |
23,896
+1,697
| +8% | +$48.4K | 0.1% | 63 |
|
|
2014
Q1 | $677K | Sell |
22,199
-422
| -2% | -$12.6K | 0.1% | 64 |
|
|
2013
Q4 | $658K | Hold |
22,621
| – | – | 0.09% | 65 |
|
|
2013
Q3 | $616K | Hold |
22,621
| – | – | 0.1% | 66 |
|
|
2013
Q2 | $601K | Buy |
+22,621
| New | +$625K | 0.1% | 67 |
|
Other funds holding PFE
TIM
Sabal Trust's PFE Position: Q1 2025 in Review
Sabal Trust increased its Pfizer (PFE) stake by 7.1% in Q1 2025, buying an estimated $1.46M and bringing the position to 837,870 shares worth $21.2M. The position accounts for 1.18% of the portfolio, ranked #43.
Sabal Trust first reported a position in PFE in Q2 2013 and has held it in 48 quarters since. The position peaked at $50.3M in Q4 2021. 2,931 funds tracked by Wall St. Rank hold PFE as of Q1 2025.
- Sabal Trust held 837,870 shares of Pfizer worth $21.2M as of Q1 2025.
- Sabal Trust bought 55,705 Pfizer shares in Q1 2025, an estimated $1.46M.
- Pfizer made up 1.18% of Sabal Trust's portfolio in Q1 2025, its #43 holding.
- Sabal Trust first reported a position in Pfizer in Q2 2013 and has held it in 48 quarters since.
- Sabal Trust's Pfizer position peaked at $50.3M in Q4 2021.
- 2,931 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.
Based on Sabal Trust's 13F filing for Q1 2025, filed 23 Apr 2025.